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Guidelines Axonal excitability studies allow deductions about membrane and ion channel properties in vivo.
 Excitability studies have investigated nerve function and pathophysiology in neurological disease.
 Guidelines summarise physiological basis, methodology and interpretation of excitability studies.
a b s t r a c t
Measurement of axonal excitability provides an in vivo indication of the properties of the nerve mem-
brane and of the ion channels expressed on these axons. Axonal excitability techniques have been utilised
to investigate the pathophysiological mechanisms underlying neurological diseases. This document pre-
sents guidelines derived for such studies, based on a consensus of international experts, and highlights
the potential difficulties when interpreting abnormalities in diseased axons. The present manuscript pro-
vides a state-of-the-art review of the findings of axonal excitability studies and their interpretation, in
addition to suggesting guidelines for the optimal performance of excitability studies.
 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open
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density of voltage gatedNa+ channels (both transient (Nat) and persistent (Nap)) at the
node of Ranvier. Slow K+ channels (Ks) are also depicted at the node. Fast K+ channels
(Kf) located adjacent to the node in the internode under the myelin sheath, as well as
the hyperpolarization activated cation conductance (Ih), slowK+ channels andvoltage-
independent leak conductances (Lk), Na+/K+ pump and the Na+/Ca2+ exchanger.1. Introduction
Axonal excitability techniques provide information about ion
channel function and surrogate markers of axonal membrane
potential in vivo in human axons. As a neurophysiological tech-
nique, axonal excitability studies have become more available in
clinical and research settings over the past 20 years, enabling
investigation of the properties of the nerve membrane as well as
pathophysiological mechanisms underlying neurological diseases.
In contrast to nerve conduction studies, axonal excitability studies
utilise submaximal stimuli to examine the properties underlying
the excitability of the axon. While nerve conduction studies mea-
sure impulse conduction, specifically the ability of axons to con-
duct between the stimulating and recording sites, axonal
excitability studies provide insight into the properties of the axonal
membrane at the site of stimulation. Given the translation and sig-
nificant uptake of axonal excitability techniques in practices
worldwide, it seems timely to produce a set of guidelines based
on a consensus of international experts.
Current axonal excitability protocols utilise threshold tracking
as a preferred technique (reviewed in Bostock et al., 1998). The
basic premise of threshold tracking techniques is to measure the
strength of the stimulus required to produce a compound action
potential (CAP) of a specified size, termed the ‘‘threshold”. Typically
the target selected corresponds to 30–40% of the maximum CAP,
which sits on the steepest portion of the stimulus-response curve
and is most responsive to change (Kiernan et al., 2000, 2001a).
When the test response is smaller than the tracking target, the
intensity of the subsequent stimulus is increased, and converselychannel subtypes and their neurophysiological roles.
ion channel subtypes Neurophysiological role
sient Na+ channels Nat Action potential generation; represent majority of Na+
current
istent Na+ channels Nap Demonstrate incomplete inactivation, modulation of
excitability
K+ channels Ks Outward rectification, limitation of ectopic firing,
Reduction of excitability following impulse trains
K+ channels Kf Dampen excitability after action potential generation
to prevent re-excitation
erpolarization
ctivated cation
onductance Ih
Stabilizing membrane potential and excitability;
inward rectification
K+ pump Maintenance of low intracellular Na+ concentration and
membrane potential
Ca2+ exchanger Removal of excess Ca2+; reverse operation can lead to
axonal injury and cell deathwhen the response is larger than the tracking target it is reduced
(Bostock et al., 1998; Burke et al., 2001). The target size may be
set to any size, but the extreme ends of the stimulus-response curve
should be avoided because large changes in current then produce
small changes in the recorded potential. Changing the stimulus
intensity so that the test potential remains the same size during dif-
ferent manoeuvres avoids ‘‘floor” and ‘‘ceiling” effects and further-
more, enables the study of axons of similar size despite changes in
their excitability (Bostock et al., 1998; Burke et al., 2001).
Most studies using threshold tracking have been undertaken on
large myelinated axons, revealing the properties of the nerve mem-
brane and of the ion channels expressed on these axons (Fig. 1;
Table 1). As with nerve conduction studies, small myelinated axons
cannot be readily studied using the excitability techniquesAxonal localization References
High density at nodes of
Ranvier
Ritchie and Rogart (1977), Schwarz et al.
(1995), Caldwell et al. (2000)
May reflect differential gating
of Nat channel population
Bostock and Rothwell (1997), Baker and
Bostock (1997), Krishnan et al. (2009)
Highest density at nodes of
Ranvier
Baker et al. (1987), Schwarz et al. (1995),
Devaux et al. (2004)
High density in juxtaparanode Chiu and Ritchie (1984), Wang et al. (1993),
Rasband et al. (1998)
Predominantly expressed at
internode
Baker et al. (1987), Pape (1996), Krishnan
et al. (2009)
Unclear localisation (nodal,
paranodal and/or internodal)
Morita et al. (1993), Alberti et al. (2007),
Krishnan et al. (2009),
Axonal membrane; Internode
and nodal regions
Steffensen et al. (1997), Persson et al.
(2010)
310 M.C. Kiernan et al. / Clinical Neurophysiology 131 (2020) 308–323reviewed in these guidelines (Krishnan et al 2009; Kiernan and Lin,
2012), but direct recordings from unmyelinated axons can be made
using microneurography. These recordings have enabled excitabil-
ity properties to be documented in patients and healthy subjects
(Serra et al., 1999; Serra, 2009; Serra et al., 2009). The underlying
physiology accessible via axonal excitability techniques will be
reviewed in the next section.
2. Physiological basis for changes in excitability
Standardised axonal excitability protocols have been developed
to optimise the utility of the technique in the clinical setting. Semi-
automated protocols utilising specialised software were initiated
at the 1999 Nordic course in clinical axonal electrophysiology as
the TROND protocol (Kiernan et al., 2000). Current axonal
excitability protocols derived from this initial protocol assess mul-
tiple measures of axonal excitability (Table 2). While threshold is a
measure of excitability and may be used as a surrogate biomarker
of membrane potential, the interpretation of threshold changes
may be confounded by a variety of factors, and it is usually neces-
sary to assess multiple threshold parameters to interpret a
recorded change in threshold (Baker and Bostock, 1989; Bostock
et al., 1994; Mogyoros et al., 1997; Grosskreutz et al., 1999, 2000).
The key elements examined in standardised axonal excitability
protocols (Fig. 2) include the stimulus-response curve and
strength-duration properties (using test stimuli of different dura-
tion), threshold electrotonus and the current/threshold relation-
ship (using subthreshold conditioning stimuli) and the recovery
cycle (using suprathreshold stimuli). These properties are
reviewed in full in Bostock et al. (1998) and Burke et al. (2001).
With the exceptions of the stimulus-response curve and
strength-duration properties, manoeuvres are designed to see
how axons behave when membrane potential is changed. No indi-
vidual ion channel is uniquely responsible for a single process, but
insights into channel activity can be derived by documenting
coherent behaviour across a full battery of tests. In addition, differ-
ent properties overlap and merge into one another such thatTable 2
Key excitability variables for median motor and sensory axons.
Motor median nerve excitability
29 healthy volunteers Kiernan et al. (2000) 15 healthy vo
SDTC (ms) 0.43 0.42
TEd peak (%) 69.6 67.3
TEd 90–100 (%) 45.7 43.1
TEh 90-100 (%) 120.8 115.7
S2 accommodation 23.97 24.2
Hyperpolarizing I/V slope 0.375 0.329
Minimum I/V slope 0.248 0.238
Resting I/V slope 0.616 0.584
RRP (ms) 3.14 3.07
Superexcitability (%) 25.4 –23.4
Subexcitability (%) 14.7 14.4
Sensory median nerve excitability
70 healthy volunteers Lai et al. (2015a) 20 healthy v
SDTC (ms) 0.617 0.59
TEd peak (%) 58.6 61.47
TEd 90–100 (%) 50.4 48.63
TEh 90-100 (%) 132.7 133.9
S2 accommodation 8.17 NR
Hyperpolarizing I/V slope 0.314 0.38
Minimum I/V slope 0.236 0.25
Resting I/V slope 0.56 0.56
RRP (ms) 3.9 3.21
Superexcitability (%) 18.7 15.22
Subexcitability (%) 12 8.54
NR: not reported.changes in an early property may have later effects e.g., the gradual
closure of slow K+ channels is a major factor in the late subex-
citable phase of the recovery cycle, but this phase is preceded by
a superexcitable phase, and changes in it will alter threshold dur-
ing the late subexcitable phase (discussed later).
2.1. Strength-duration properties
The strength-duration time constant (sSD) assesses the relation-
ship between the strength and duration of a stimulus and is related
to both active and passive membrane properties (Fig. 2A). The
‘‘passive” membrane time constant measures the time for mem-
brane potential to decay in an exponential fashion and this value
has been estimated to be 45–50 ms for human nerve, and is similar
for motor and sensory axons (Bostock and Rothwell, 1997). How-
ever in axons, the injected current will alter membrane potential
and thereby the activity of channels active within that voltage
range, and this will slow the recovery from a test pulse. Accord-
ingly, the strength-duration time constant in human axons is typ-
ically 450–600 ms.
In normal nerve, the major voltage-dependent channels active
near resting threshold are persistent Na+ channels and slow K+
channels, and both are activated more by membrane depolariza-
tion. The only Na+ channel expressed at the mature mammalian
node of Ranvier is thought to be Nav1.6 (Caldwell et al., 2000),
but this channel can have two gating modes: transient and persis-
tent. The majority of channels (perhaps 98%) behave in the classical
Hodgkin/Huxley manner, opening when depolarized sufficiently,
inactivating when held depolarized, and closing when returned
to or below resting membrane potential. It is estimated that 30%
channels are inactivated at resting membrane potential (Schwarz
et al., 1995). Some channels do not inactivate or do so slowly when
held depolarized, and they therefore continue to pass a persistent
inward Na+ current that is de-stabilizing: they depolarize the
membrane further and that opens more Na+ channels, producing
greater depolarization. The voltage for activation of channels with
persistent gating is depolarized by 15 mV compared to transientlunteers Tomlinson et al. (2010) 105 healthy volunteers McHugh et al. (2011)
0.52
69.1
44.8
121.4
NR
0.35
0.25
0.59
3.0
–23.6
14.9
olunteers Matamala et al. (2018) 33 healthy volunteers Sung et al. (2017)
0.62
59.36
49.06
145.44
10.3
0.39
0.24
0.55
3.44
16.61
12.39
Fig. 2. Excitability parameters. (A) Plot of stimulus width and threshold charge with the strength-duration time constant (ssd) as the negative intercept on the x-axis. (B)
Recovery cycle with the relative refractory period, superexcitability and subexcitability depicted on the figure. The timing of conditioning stimuli is depicted in the box to the
right.
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potential (and can be ‘‘turned off” by a hyperpolarizing test current
in the technique of latent addition; Bostock and Rothwell, 1997).2.2. Recovery cycle
The recovery cycle utilises paired pulses with varying interstim-
ulus intervals (typically between 2 and 200 ms) to assess the
recovery of excitability following impulse conduction (Fig. 2B).
The components of the recovery cycle overlap, such that changes
in one phase will have effects on the size of subsequent phases.
It is generally accepted that the major determinant of the recovery
from refractoriness in normal mammalian myelinated axons is the
recovery of Na+ channels from inactivation (Schwarz et al., 1995).
K+ channels with fast kinetics contribute little because they are lar-
gely located in the juxta-paranodal region under the myelin, and
there is little access to them over the time course of refractoriness.
However there can be more ready access to these channels when
the integrity of the paranodal seal is disrupted by disease (e.g.,
paranodal demyelination; Jankelowitz and Burke, 2013; Garg
et al., 2018 or by structural deficiency (e.g., in ALS; Howells et al.,
2018a). It is commonly claimed that slow K+ channels cannot con-
tribute to limiting the refractory period because of their slow open-
ing kinetics, but 35% of slow K+ channels are open at rest and can
pass current during the action potential (Burke et al., 2009),
thereby limiting the action current and promoting repolarization.
In myelinated axons, superexcitability reflects the size of the
depolarizing afterpotential. This produces re-excitation of the node
by the ‘‘back-flow” of current from the internodal membrane
through low resistance pathways under and through the myelin
sheath (Barrett and Barrett, 1982). The amount of current stored
on the internodal membrane varies with membrane potential as
paranodal fast K+ channels are opened or closed. Hyperpolarization
will close open fast K+ channels, increasing the depolarizing after-
potential and the extent of superexcitability. Depolarization will
open channels, decreasing the depolarizing afterpotential and
thereby the extent of superexcitability. The superexcitable phase
normally ends 15–20 ms after the conditioning discharge, but it
may last 100 ms when axons are hyperpolarized (see Fig. 7 in
Howells et al., 2013).
Late subexcitability is due to axonal hyperpolarization and sub-
sides with the gradual closure of slow K+ channels opened during
the conditioning discharge. Axons begin to become subexcitable
at 15 ms, peak subexcitability occurs around 35 ms, and this thendecays to resting values at 100 ms. This time course does not
reflect the slow K+ current, which starts much earlier, but is insuf-
ficient to raise threshold until superexcitability has waned. As a
result, the degree of subexcitability does not provide a pure mea-
sure of slow K+ channel activity because it is a balance between
the decaying slow K+ current and decaying superexcitability. A
measure of slow K+ channel activity less contaminated by superex-
citability can be obtained by recording a recovery cycle using two
conditioning stimuli 4 ms apart, and then subtracting the recovery
cycle recorded using a single conditioning stimulus (Shibuta et al.,
2010a; see Fig. 3 in Matamala et al., 2018).2.3. Threshold electrotonus
Threshold electrotonus indirectly examines membrane poten-
tial changes that occur during long subthreshold current pulses,
demonstrating properties of the internodal membrane (Burke
et al., 2001). The standard threshold electrotonus protocol intro-
duced by Kiernan et al. (2000) used conditioning polarizing cur-
rents that were insufficient to activate axons directly and which
lasted 100 ms. However, stronger and longer hyperpolarizing cur-
rents, e.g., 100% of threshold applied for 300 ms, are required to
see the full extent of accommodation to hyperpolarization
(Tomlinson et al., 2010; Howells et al., 2012).
Accommodation to depolarizing currents depends on two types
of K+ channel, ‘fast’ (Kf) channels of the KV1 family, and ‘slow’ (Ks)
channels of the KV7 family. The Kf currents primarily limit the early
responses to depolarizing currents (labelled the S1 phase in
Fig. 3A) while the Ks currents are responsible for the decline in
depolarizing electrotonus after the peak (labelled the S2 phase in
Fig. 3A). The separate contributions of these two K+ channel types
to electrotonus was resolved by pharmacological blockade in rat
axons (Baker et al., 1987), and is evident in threshold electrotonus
of human axons in K+ channelopathies (Tomlinson et al., 2010,
2012).
Accommodation to hyperpolarization is produced by
‘‘hyperpolarization-activated cyclic nucleotide-gated” (HCN) chan-
nels which pass the hyperpolarization-activated current Ih. The
other voltage-dependent currents are switched off, except for the
leak current, an ohmic conductance originally thought not to
involve specific channels. With weak hyperpolarization, there is
both the closure of channels active at rest (mainly the persistent
Na+ current and the slow K+ current) and activation of Ih. However
when axons are hyperpolarized beyond 60% threshold, it is likely
Fig. 3. Excitability parameters. (A) Threshold electrotonus with the initial response to polarization (F phase) followed by slow threshold change (S1 phase) and
accommodation to depolarization (S2 phase). Conditioning stimulus current waveforms utilized to generate threshold electrotonus are depicted below. (B) Current-threshold
(I/V) relationship plotted with response to hyperpolarizing current in the lower left quadrant and response to depolarizing current in the upper right quadrant. Conditioning
stimulus current waveforms utilized to generate the current-threshold relationship are depicted below.
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Both contribute to the accommodative change in membrane
potential. There are four HCN isoforms, and which one or ones
are expressed on human peripheral nerve are uncertain. Given
the very long time constant of some isoforms, they may be mani-
fest only as a change in membrane potential. There is evidence
for human motor axons that an Ih isoform (probably HCN1) is
active at resting membrane potential and contributes to the lower
threshold of the first recruited axons (Trevillion et al., 2010). When
the hyperpolarizing current ends, there is a slowly developing
long-lasting decrease in threshold which is due to gradual closure
of HCN channels and re-activation of persistent Na+ currents.
For valid threshold electrotonus, it is important to check that
the depolarizing (and hyperpolarizing) currents are subthreshold.
If axons are hyperexcitable or depolarized, the conditioning depo-
larizing current may cause them to discharge even when the
strength of the current is only 40% of threshold (Trevillion et al.,
2007). This occurs rarely with healthy motor axons, but frequently
with healthy sensory axons (Burke et al., 2007). When there is a
discontinuity or ‘‘notch” in the development of the peak depolariz-
ing change in threshold, it is advised to inspect the raw traces look-
ing for inadvertent discharge in response to the supposedly
subthreshold depolarization. The traces with this contamination
cannot be used in modelling and, when present, additional thresh-
old electrotonus curves should be recorded using weaker depolar-
izing currents.
Compared to other measures, there is marked variability in the
threshold electrotonus curves to hyperpolarizing currents. This
variability appears to be subject-specific: the between-subject
variability is much greater than the within-subject variability
(Tomlinson et al., 2010; Howells et al., 2013), and this is explicable
by differences in channel gating, specifically the voltage for half-activation of a single type of HCN channel (Jankelowitz et al.,
2007; Howells et al., 2012). Similarly, the well-documented differ-
ence in Ih in sensory and motor axons (Bostock et al., 1994; Lin
et al., 2002) is probably not due solely to a difference in expression
of Ih. The difference in expression accounts for only some 39% of
the difference in Ih, while the rest can be accounted for by a differ-
ence in channel gating (Howells et al., 2012). The important mes-
sage for future studies is that changes in channel activity do not
necessarily reflect changes in the expression of the channel: they
could result from changes in the gating of a similar number of
channels.
2.4. Current-threshold relationship
To explore the accommodative properties axons better, the
original Trond protocol incorporated the current-threshold rela-
tionship, as an analogue of a current-voltage (I/V) relationship
(Fig. 3B). Hyperpolarizing and depolarizing currents lasting
200 ms are utilised and the strength of the injected current is
stepped from 100% (hyperpolarizing) to +50% (depolarizing).
The effect on membrane potential is indicated by the change in
threshold at the end of the injected current. The subsequent 16
measurements (10 hyperpolarizing, zero, 5 depolarizing) form
the current-threshold relationship, effectively the ‘‘I/V curve”,
which enables quantification of the resting input conductance
and inwardly and outwardly rectifying conductances (Kiernan
and Bostock, 2000; Kiernan et al., 2000).
The resting I/V slope (the slope of the I/V curve immediately
above and below zero current injection) is a threshold analogue
of the resting input conductance, and will be affected by channels
open at resting membrane potential. The steepness of the curve in
the depolarizing and hyperpolarizing directions reflects inward
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accommodated to the change in membrane potential – the smaller
the change in threshold for an injected current, the greater the
accommodation. In the depolarising direction, the accommodation
is due to K+ currents; in the hyperpolarizing direction it is due to Ih.
These accommodative changes are best seen in the I/V slope
curves, where the slope of the I/V curve is plotted against the
change in threshold.
2.5. Latent addition
Latent addition using automatic threshold tracking is mainly
used to study persistent Na+ currents at the node of Ranvier
(Bostock and Rothwell, 1997; Kuwabara et al., 2006; Misawa
et al., 2006; Kuwabara and Misawa, 2008). Although strength-
duration time constant is also used as a surrogate measure of per-
sistent Na+ currents, it is affected by passive membrane properties.
Latent addition can evaluate these two factors separately, and this
is the major advantage of this technique (Kuwabara and Misawa,
2008). In brief, latent addition utilises short stimuli (60 ms), with
hyperpolarizing conditioning stimuli set to 90% of threshold
and a variable conditioning-test interval. The threshold recovery
after hyperpolarization is represented by the sum of two exponen-
tials - the fast component reflecting passive membrane properties
and the slow component indicating persistent Na+ conductances
(Bostock and Rothwell, 1997).
2.6. Unmyelinated axons
Unmyelinated axons cannot be studied directly in routine con-
duction studies and the techniques and excitability properties
described earlier are not present or have a different basis. However
they subserve important sensations, warranting a brief review of
their properties.
Within peripheral nerve, axons with diameters of more than
1 mm tend to be myelinated, while axons with diameters of less
than 1 mm tend to be unmyelinated (Waxman and Bennett,
1972). These unmyelinated axons, termed C-fibres, arise from
small-diameter neurons in the dorsal root ganglion (Waddell and
Lawson, 1990). Within peripheral nerves and roots, the unmyeli-
nated axons run either singly, or in small groups in which they
can be juxtaposed, within furrows of investing but non-
myelinating Schwann cells (Ochoa and Mair, 1969). In contrast to
myelinated axons which conduct action potentials in a saltatory
manner, conduction along unmyelinated axons proceeds along
the fibre in a continuous manner. The continuous mode of conduc-
tion in unmyelinated axons is partly a consequence of the absence
of low-capacitance, high-resistance myelin sheaths, and appears to
be supported by a relatively homogeneous distribution of Na+
channels along the axonal trajectory. In terms of sodium channels,
Nav1.1 (Black et al., 1996), Nav1.7, Nav1.8, and Nav1.9 (Persson
et al., 2010) and Nav1.6 (Black et al., 2002) have been detected
immunocytochemically along the shafts of unmyelinated PNS
axons, although these studies do not differentiate between intracy-
toplasmic channels and functional channels inserted into the axo-
nal membrane. The overall density of Na+ channels within the
membrane of unmyelinated axons has been roughly estimated at
about 102 per mm2 (Pellegrino et al., 1984). Conduction velocity
along unmyelinated peripheral nerve axons is generally less than
1–2 m/s, slower than in myelinated axons of the same diameter.
Because the surrounding Schwann cells do not seal off unmyeli-
nated axons from the surrounding extracellular milieu, these axons
can be influenced by changes in the ionic microenvironment.
Unmyelinated axons (C-fibres) subserve functions such as tem-
perature and pain sensation. Their dysfunction is not necessarily
accompanied by objective signs on neurological examination, suchas the hyporeflexia that accompanies dysfunction of larger myeli-
nated axons. This underscores the importance of electrophysiolog-
ical assessment by microneurography (e.g. Serra et al., 1999; Serra,
2009; Serra et al., 2009).
3. Hardware and software requirements
Threshold tracking typically utilises QTracS software (
UCL Institute of Neurology, London, UK, available from Digitimer
Ltd at www.Digitimer.com), a nerve excitability stimulus control,
acquisition and data analysis software package (Fig. 4) with a num-
ber of relevant features:
 a choice of tracking modes for determining the step size, from
fixed step (e.g., 2%) to proportional step (i.e., step size propor-
tional to difference between actual and target response;
 the ability to cycle between different stimulus channels, each
with different conditioning and test stimulus combinations,
keeping separate records of the threshold and tracking history
for each;
 the option to fix the amplitude of the conditioning stimulus on
one channel to a specified fraction of the test stimulus on
another channel, used, e.g., for latent addition and threshold
electrotonus;
 the option to subtract the response on one channel from that on
another, before comparing the response with the target
response (e.g., in measurements of the recovery cycle when
the conditioning-test interval is short, and the response to the
conditioning stimulus overlaps with the response to the test
stimulus); and
 the option to increment one of a number of time intervals (e.g.,
the conditioning–test interval), either in regular steps or in a
predetermined irregular sequence, and either after a fixed num-
ber of test stimuli or only when threshold has been determined
to a specified accuracy.
Axonal excitability data generated by the TROND protocols can
be analysed directly in QtracP ( UCL Institute of Neurology, Lon-
don, UK, available from Digitimer Ltd at www.Digitimer.com),
which creates to special text files (.MEM) for further analysis. Com-
plete nerve excitability data from a group of MEM files indexed by
a MEF file can be plotted or exported to an Excel file.
3.1. Stimulator
The DS5 isolated bipolar stimulator developed by Digitimer Ltd
allows computerised control of stimulus amplitude and timing
parameters and has a maximal constant current output of ±50 mA.
The DS5 is controlled by an analogue voltage input which it trans-
lates into an isolated constant-current stimulus (up to ±50 mA),
precisely replicating the shape of the input waveform.
3.2. Data acquisition system
The National Instruments (NI) USB-6341 with BNC terminals
(Part 782251-01) is suitable for threshold tracking. The QtracS dri-
ver sets up the NI cards with an input range of ± 10 V and 8 differ-
ential inputs (AI0-7). NI-DAQmx software must be version 7.5 or
later. If speed is critical, PCI boards are faster than USB boards (ref-
erence source: Qtrac manual 2016 version).
3.3. Amplifier
For axonal excitability testing, compound action potentials have
to be amplified (100 to 20k) and bandpass filtered (3 Hz to
Fig. 4. Setup for testing human axonal excitability. Depiction of testing setup demonstrating connectivity of computer, data acquisition board, stimulator, amplification
devices and patient.
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it compatible with commercial data acquisition systems. The D440
amplifier was designed by Digitimer specifically for nerve
excitability studies on both sensory and motor nerves. It has good
low-noise performance suitable for recording submaximal sensory
nerve action potentials (SNAPs). In addition, Howells et al. (2018b)
have developed a bespoke amplifier to be able to track small SNAPs
of only a few microvolts amplitude.4. Important controls
4.1. General considerations
Axonal excitability techniques have primarily been utilised to
identify pathophysiological mechanisms, rather than to serve as
diagnostic tools. As such, the determination of diagnostic cut-off
values and estimates of diagnostic accuracy and precision (as per
the STARD criteria) would be required before axonal excitability
studies would be considered implementable for routine diagnostic
purposes. However, excitability studies are useful in the clinical
setting, in the context of providing pathophysiological insights that
are complementary to other electrodiagnostic tests and clinical
findings.
At an individual patient level, axonal excitability studies can
produce results that distinguish individual patients from healthy
controls (e.g. including oxaliplatin-induced neurotoxicity in sen-
sory axons Park et al., 2009b; multifocal motor neuropathy in
affected motor axons Kiernan et al., 2002a; hereditary neuropathy
with liability to pressure palsies Jankelowitz and Burke, 2013;
Farrar et al., 2014; episodic ataxia type 1 Tomlinson et al., 2010;
Tan et al., 2013; renal neuropathy Kiernan et al., 2002b; Krishnan
et al., 2005b). The number of control subjects needed varies across
disorders. Because excitability studies provide information about
axonal membrane function through a number of parameters, it is
not possible to define a standard of abnormality that would be
appropriate across multiple disorders and hence to define a mini-mum sample size of healthy controls that would be suitable across
conditions.
However, of note, routine electrodiagnostic values are not
always distinct from healthy controls and individual patients,
and reference values solely provide information on the probability
of an individual’s results being abnormal (Campbell and Robinson,
1993). Taken in total, excitability studies provide evidence to aid
diagnosis and distinguish conditions from disease mimics, how-
ever should be utilized in the context of clinical findings.
Regarding factors which may be important in terms of influenc-
ing excitability recordings, there is evidence that potassium and
sodium blood levels (Kuwabara et al., 2007; Boërio et al., 2014;
Park et al., 2014), ion channel active medications and temperature
are particularly relevant. A number of drugs have purported effects
on ion channel function, and may therefore influence peripheral
nerve excitability, however exact effects remain unclear. Of these
riluzole (Vucic et al., 2013), mexilitene (Kuwabara et al., 2005),
lidocaine (Moldovan et al., 2014) and flupirtine (Fleckenstein
et al., 2013) have been demonstrated to affect peripheral nerve
excitability.4.2. Noise elimination
Signals recorded using biological or other high impedance
devices are often contaminated with 50 Hz noise. This electrical
interference may be extremely difficult to remove without altering
the original signal embedded within the noise, though attention to
grounding preparation and appropriate shielding can reduce or
eliminate electrical interference. The Hum Bug (Quest Scientific
Instruments, North Vancouver, Canada) can eliminate 50 Hz noise
from analogue signals. It is equally effective at removing noise
associated with inadequate grounding, ground loops, and electrical
pick up. The Hum Bug is not a filter, it does not create phase delays,
amplitude errors, DC shifts, or waveform distortion. It is connected
between preamplifier and data acquisition device. Hum Bug is par-
ticularly useful when testing sensory nerve excitability, because
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signal-to-noise ratio is low.
Assessment of temperature: Skin temperature should be mea-
sured at the site of stimulation throughout the test, and kept
stable, greater than 32 C. The relative refractory period is very
sensitive to temperature and may be prolonged by cooling because
of slowed channel kinetics at lower temperatures (Stys and Ashby,
1990; Burke et al., 1999; Kiernan et al., 2001b; Mogyoros et al.,
2000), and axonal depolarization due to an effect of cooling on
Na+/K+-pump activity (Franssen et al., 2010; Kovalchuk et al.,
2018). Hyperthermia may challenge the ability of diseased axons
to transmit action potentials faithfully (Howells et al., 2013): there
were clear changes in excitability during hyperthermia, with
reduced superexcitability following an action potential, faster
accommodation to long-lasting depolarization and reduced accom-
modation to hyperpolarization.
4.3. Methodological and practical considerations
Stimulation
1. Select appropriate stimulating electrodes. If the current density
is greater than 2 mA rms/cm2, the patient might be at risk of
burns at the stimulation site.
2. Do not connect the stimulator to patients and high-frequency
surgical equipment or microwaves concurrently. Doing so could
cause burns, and the output of stimulator will be affected.
3. The stimulator should not be operated in strong magnetic fields,
such as in an MRI scanning room.
4. Stimulators should not be applied to patients thoracically or
trans-thoracically because this increases the risk of cardiac
fibrillation.
5. Patients with cardiac pacemaker should not undergo the nerve
excitability test without specialist’s medical advice.
Recording
Axonal excitability studies require stable tracking of stimulus cur-
rent over the course of the test – accordingly threshold and uncon-
ditioned response should be monitored to ensure that major
changes do not occur. Manoeuvers such as ischaemia or activity
may reduce the amplitude of the maximal response, necessitating
continuous monitoring of responses during assessment (Kiernan
et al., 1997; Mogyoros et al., 1997; Lin et al., 2002). Identification
of the optimal stimulation site in terms of lowest threshold is
important, as is appropriate skin preparation to reduce impedance.
Provided that conduction is maintained, there is no theoretical
limit regarding the number of axons contributing to the recorded
response, because the tracking mode can be adjusted to track the
activity of single motor units. Stimulation rates should be kept
slower than 3 Hz, to avoid cumulative effects. When length-
dependent involvement is suspected it could be relevant to study
excitability at multiple sites along the same nerve. In the upper
limb, proximal stimulation along the median nerve is typically car-
ried out at elbow with recording over the forearm flexors (such as
flexor carpi radialis). In other studies, recording has been carried
out also over abductor pollicis brevis to ensure that the same axons
were studied (Moldovan et al., 2014). In the lower limb, excitability
of the peroneal nerve at the fibular neck has been tested by record-
ing from tibialis anterior (Kuwabara et al., 2001, 2002a), and a
length-dependent gradient was established by recording from tib-
ialis anterior, extensor digitorum brevis, and abductor hallucis
(Krishnan et al. 2004; 2005a, 2006a; Kuwabara et al., 2001;
Boland et al., 2009). It has been suggested that differences in bio-
physical properties could contribute to differences in susceptibility
to neuropathy (Van der Heyden et al., 2013; Lin et al., 2000). Spe-cialized recordings have assessed facial nerve branches (Eviston
and Krishnan, 2016) as well as a preliminary report on the spinal
accessory nerve in severe demyelinating CMT when median nerve
studies were not possible (Krarup et al., 2017; Pisciotta et al.,
2018).5. Interpretation of clinical results: the role of mathematical
modelling
Nerve excitability properties depend on the complex interac-
tions between nodal and internodal ion channels and ion pumps,
passive membrane components, and the intracellular and extracel-
lular constituents of the nerve. Because of this complexity, it can be
very difficult to predict the effects of any pathological change, and
even more difficult to deduce the biophysical basis of an abnormal
nerve excitability recording. However, a simplified mathematical
model has been generated that accounts quite well for the com-
mon nerve excitability measurements made on normal human
peripheral motor axons, and in certain favourable situations this
can be helpful in the interpretation of abnormal recordings (for
examples see references Kiernan et al., 2005a; Howells et al.,
2018a).
If considering the use of modelling to aid interpretation of
recordings from a group of patients, it is important to bear in mind
that:
(a) nerve excitability recordings depend on the properties of
multiple nerve fibres at a single site, so modelling is likely
to be helpful only if the axons are uniformly affected, across
both the width and length of the nerve;
(b) patient excitability measurements need to be consistently
and substantially abnormal (e.g. with no overlap in some
parameters between interquartile ranges of patient and con-
trol groups) to provide enough information to model the
difference;
(c) if patient excitability properties are only abnormal in refrac-
toriness, the defect is likely to be confined to the motor
nerve terminals, neuromuscular junction or muscle, and
modelling nerve excitability in the nerve trunk will be
unhelpful;
(d) there are small but significant changes in nerve excitability
with age and temperature (but not sex, Casanova et al.,
2014), so that it is desirable to first assemble a control set
of recordings which match in these variables. There are also
age-related changes that occur with nerve maturation in
children (Farrar et al., 2013). Mathematical modelling of
nerve excitability abnormalities has been applied to a range
of neurological conditions, and some examples will be high-
lighted in relation to their utility in interpreting patient
recordings in the clinical studies section that follows.
6. Clinical studies
6.1. Immune-mediated neuropathies
In acquired neuropathies, paranodal or internodal demyelina-
tion results in exposure of ion channels, and changes in myelin
resistance, whereas immune attack on the nodal axolemma can
impair sodium channel function at the node. The structural
changes can cause complex alterations in axonal properties. Most
excitability studies have compared data from patient groups with
normals or disease controls. Each type of immune-mediated neu-
ropathy tends to show characteristic findings, according to its
pathophysiology, and nerve excitability studies can provide useful
information about the pathology, diagnosis, and treatment. Specif-
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paired studies pre- and post-treatment (such as before and after
infusion with intravenous immunoglobulin).
In immune-mediated neuropathies such as Guillain-Barré syn-
drome (GBS) and chronic inflammatory demyelinating polyneu-
ropathy (CIDP), the distal nerve terminals and nerve roots, where
the blood-nerve barrier is anatomically deficient, are preferentially
affected by the immune attack. Therefore, excitability indices may
be normal at the tested site such as the median nerve at the wrist.
This is the case in the early phase of GBS, but not in CIDP.
GBS is currently classified as acute inflammatory demyelinating
polyneuropathy (AIDP), the classical demyelinating form, or acute
motor (and sensory) axonal neuropathy (AMAN/AMSAN), an axo-
nal variant. The pathology in the two subtypes is different, and
so too are the excitability changes. Three studies have compared
excitability properties in AIDP and AMAN/AMSAN (Kuwabara
et al., 2002a, 2003; Pyun et al., 2017). All excitability indices
(sSD, threshold electrotonus, recovery cycle, and current/threshold
relationship) were normal, findings explained by demyelinating
lesions selectively affecting the nerve terminals and roots, sparing
the wrist portion where testing was performed.
In contrast, patients with AMAN/AMSAN have high refractori-
ness and an impaired refractory period of transmission. When
pairs of stimuli were delivered at short intervals (2 ms), the second
impulse was blocked due to inactivation of nodal sodium channels
by the conditioning discharge. Among excitability indices, this was
the single abnormality, suggesting that nodal sodium channels
were impaired by anti-ganglioside antibodies. Specifically, gan-
glioside GM1 and GD1a constitute a lipid raft of the axonal mem-
brane, and deposition of antibodies against these structures
impairs nodal structures such as sodium channels. As such, axonal
excitability testing can be recommended in axonal GBS patients to
assess sodium channel function and the safety factor for impulse
transmission in the distal motor nerve terminals.
In contrast, for patients diagnosed with CIDP, the median nerve
at the wrist is commonly affected by demyelination. Segmental
demyelination reduces myelin resistance and exposes ion chan-
nels. Two studies reported multiple abnormalities in excitability
measurements for typical CIDP (Cappelen-Smith et al., 2001;
Sung et al., 2004). The most striking changes were observed in
threshold electrotonus, with a significant ‘‘fanning-out” (i.e.,
greater threshold changes to the long conditioning depolarizing
and hyperpolarizing currents). Similarly, Sung et al. (2004) found
that 48% of CIDP patients had abnormal threshold electrotonus
that correlated with disease duration and severity, with a poorer
response to immunotherapies. As such, threshold electrotonus
may be useful to detect demyelination to provide new insights into
the pathophysiology and distribution patterns of demyelination in
CIDP (Garg et al., 2017).
Subsequently, Lin et al. (2011) established that many of the
excitability indices, such as sSD, threshold electrotonus, and
superexcitability, changed immediately after the start of intra-
venous immunoglobulin therapy, a rapid response to the modula-
tory effects of immunoglobulin treatment. Sung et al. (2014)
reported that by measuring superexcitability, subexcitability and
hyperpolarizing threshold electrotonus (10–20 ms), patients with
AIDP and acute-onset CIDP could be clearly separated into two
non-overlapping groups. Nerve excitability techniques may be use-
ful in distinguishing acute-onset CIDP from AIDP at the initial
stage, leading to more directed and appropriate treatment.
While there may remain some debate about the nature of mul-
tifocal motor neuropathy (MMN) and specifically whether the con-
dition represents a demyelinating or axonal disease, a number of
studies have addressed the pathophysiology of MMN and the cause
of focal conduction block. Axonal properties remote from foci of
conduction block are normal, findings that support the contentionthat MMN is not a generalized disease with a focal presentation
(Cappelen-Smith et al., 2002). However, excitability studies have
also been undertaken in MMN patients just distal to the site of con-
duction block in affected nerves, with strikingly abnormal findings
(Fig. 5A; Kiernan et al., 2002a; Garg et al., 2017). The most signifi-
cant alterations in excitability properties in the MMN patients
were: (a) the reduction in minimum slope of the current/threshold
(‘I/V’) relationship (indicating a reduction in input conductance);
(b) the ‘‘fanning-out” of threshold electrotonus; and (c) the
increase in superexcitability recorded during the recovery cycle.
All these excitability parameters, highly abnormal in the MMN
patients, depend on the resting conductance of the paranodal
and internodal axon membrane. As a consequence of these find-
ings, it was hypothesised that the nerve distal to the site of conduc-
tion block in MMN patients was behaving as if hyperpolarized,
most closely resembling a post-ischaemic nerve.6.2. Hereditary neuropathies
There have been a range of excitability approaches across a
wide spectrum of hereditary neuropathy. In terms of hereditary
sensorimotor neuropathy, 4 studies undertaken in Charcot Marie
Tooth Disease CMT1A and CMTX (Nodera et al., 2004; Sung et al.,
2004; Jankelowitz and Burke, 2013; Liang et al., 2014) identified
an increase in stimulation threshold associated with ‘fanning-
out” of threshold electrotonus associated with subtle changes in
the recovery cycle consistent with changes in passive cable proper-
ties. Nevertheless, as compared to CMTX, CMT1A showed higher
threshold currents, smaller changes in TEh (90–100 ms) and a
reduced superexcitability. These findings were taken to indicate
that in CMT there were also changes in active membrane proper-
ties which could differentiate between different CMT mutations
at group level, as also supported by preliminary reports in CMT1B
where the culprit relates to mutation in the MPZ gene (Krarup
et al., 2017; Pisciotta et al., 2018).
In relation to the condition hereditary neuropathy with liability
to pressure palsies (HNPP), results from 3 excitability studies
(Jankelowitz and Burke, 2013; Farrar et al., 2014; Liang et al.,
2014) indicated that both motor and sensory excitability tests
were abnormal in HNPP. The abnormalities included an increased
simulation threshold and ‘‘fanning-out” of the threshold electro-
tonus. Although these deviations were not specific to HNPP, the
extent of the increase in threshold during hyperpolarization as
well as the heterogeneity of abnormalities across stimulation sites
provided a mechanism to differentiate HNPP from CMT1A at group
level.
Studies on amyloid neuropathy remain limited, with a single
report on threshold tracking undertaken in 10 patients with pri-
mary amyloidosis confirmed by nerve conduction studies (Hafner
et al., 2015; Lai et al., 2015). The study identified decreased
excitability of sensory fibres but otherwise there were no further
abnormalities in threshold tracking of motor or sensory fibres.
Threshold tracking in patients diagnosed with Fabry disease
harbouring an X-linked a-galactosidase mutation identified
reduced threshold reduction to depolarizing electrotonus and
reduced superexcitability. These findings were determined to be
consistent with nerve fibre depolarization possibly due to ischemia
caused by glycosphingolipid accumulation in vascular endothelial
cells (Tan et al., 2005). ‘‘Fanning-in” of motor fibres was confirmed
in another study that also identified a steeper relationship of the
hyperpolarizing current/threshold (I/V) relationship indicating
increased Ih (HCN) function that was correlated with clinical neu-
ropathy scores (Geevasinga et al., 2012). This upregulation of Ih
was suggested to be associated with features of pain as experi-
enced by patients diagnosed with the disorder.
Fig. 5. Alterations in axonal excitability in the clinical setting. Left panels depict threshold electrotonus (±40% threshold) and right panels depict recovery cycle recordings.
Dashed lines represent healthy control values and black dots represent patient values. (A) Multifocal motor neuropathy: demonstrating threshold increase in threshold
electrotonus and increased superexcitability in recovery cycle in affected motor median nerve, (B) End-stage kidney disease: demonstrating threshold reduction in threshold
electrotonus and reduction of superexcitability in recovery cycle in motor median nerve, (C) Oxaliplatin neurotoxicity: demonstrating threshold increase in hyperpolarizing
threshold electrotonus and reduced refractoriness in recovery cycle in sensory median nerve.
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pathophysiology of porphyric neuropathy (Lin et al., 2008, 2011),
patients diagnosed with latent acute intermittent porphyria (AIP)
but without superadded neuropathy, threshold tracking showed
greater mean threshold changes during hyperpolarizing threshold
electrotonus and a decrease of the current/threshold (I/V) slope
during hyperpolarization. Mathematical modeling of these record-
ings showed that such changes could be explained through reduc-
tion in Ih (HCN) current. Separately, a patient who was diagnosed
with acute neuropathy during an AIP attack showed changes con-
sistent with axonal depolarization, which was interpreted as evi-
dence of failure of the Na+/K+-pump within the axonal
membrane. The interpretation of reduced Ih in porphyria suggested
an intracellular energy failure affecting the function or level of
cAMP (Lin et al., 2008). Thus, threshold tracking can be useful inacute neuropathy in AIP as the changes appear to differentiate
from axonal GBS (Kuwabara et al., 2002c).
6.3. Epilepsy
Excitability testing in patients diagnosed with epilepsy linked
to known genetic mutations has a role in research and has demon-
strated that channelopathies affecting the central nervous system
may also express changes in peripheral nerve function, where
these channels are similarly co-expressed (Tomlinson et al.,
2018). Examples include mutations in SCN1A and SCN2A on chro-
mosome 2q24 that encode for a-subunits of Nav1.1 (SCN1A) and
Nav1.2 (SCN2A), implicated in a variety of genetic epilepsy syn-
dromes (Kullmann, 2010; Meisler et al., 2010), although these con-
ditions have yet to be examined using excitability techniques.
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b1-subunit reduces Na+-channel trafficking and has been linked to
GEFS+. Threshold tracking of peripheral nerve in patients with GEFS
+ due to a mutation in SCN1B implicating the b1-subunit in NaV1.6
channel function in myelinated fibres (Kiernan et al., 2005b) estab-
lished reduced Na+ current based on a shorter sSD, less refractori-
ness and larger fanning-out during hyperpolarizing threshold
electrotonus. These findings were similar to results in patients
experiencing tetrodotoxin poisoning, with reduction in the func-
tion of axonal Na+ channels (Kiernan et al., 2005a).
Threshold tracking in patients diagnosed with benign familial
neonatal seizures (BFNS) due to a mutation in KCNQ2 (Tomlinson
et al., 2012) established reduced accommodation during depolariz-
ing threshold electrotonus, consistent with reduced slow K+-
current as had previously been demonstrated in animal models
(Schwarz et al., 2006). Interestingly these patients did not demon-
strate peripheral nerve hyperexcitability as has otherwise been
found in patients with disturbed KV7.2 channels (Wuttke et al.,
2007; Maljevic et al., 2010) which could be explained by an adap-
tive increase in fast potassium current.
Excitability studies have also been undertaken in the related
condition episodic ataxia types 1 and 2 (EA1, EA2 Tomlinson
et al., 2010, 2016). Patients with EA1 and neuromyotonia linked
to mutation in KV1.1 identified abnormalities consistent with
markedly decreased threshold during depolarizing threshold elec-
trotonus and during the superexcitable period. In contrast, changes
in excitability in EA2 patients could not be accounted for by
changes in a single channel, and mathematical modelling was
more suggestive of involvement of Schwann cells and opening of
the Barrett-Barrett resistance.
6.4. Neurodegeneration
Excitability techniques have provided insights into the patho-
physiological mechanisms underlying the development of neu-
rodegeneration and clinical features of amyotrophic lateral
sclerosis (ALS) and related neuromuscular disorders. Prolonged
sSD, increased superexcitability and abnormalities of threshold
electrotonus have been identified as a signature of axonal dysfunc-
tion in ALS across multiple studies. These changes have been linked
to changes in ion channel function, particularly increased Na+ and
decreased axonal K+ conductances, a profile which may lead to
neurodegeneration and contribute to symptoms such as fascicula-
tions and muscle cramps (de Carvalho et al., 2017; Tsugawa et al.,
2018). Increased sSD has been identified in sporadic ALS (Mogyoros
et al., 1998; Kanai et al., 2006; Vucic and Kiernan, 2006; Vucic
et al., 2007), as well as in atypical ALS phenotypes, such as the flail
arm variant (Vucic and Kiernan, 2007a), and in familial forms of
ALS linked to superoxide dismutase-1 (SOD1) and c9orf72 (Vucic
et al., 2008; Vucic and Kiernan, 2010; Geevasinga et al., 2015). Pro-
longation of sSD in ALS has been linked to upregulation of persis-
tent Na+ conductances (Kuo et al., 2005), with additional
contribution from reduced fast and slow K+ channel conductances
producing depolarization (Vucic and Kiernan, 2006). Interestingly,
increased sSD has been linked to shorter survival in ALS (Kanai
et al., 2012), further suggesting that axonal hyperexcitability is
pathological important.
In combination with these abnormalities in sSD, changes in
threshold electrotonus and recovery cycle have been identified in
sporadic ALS. Increased threshold changes in depolarizing and
hyperpolarizing subthreshold currents (a ‘‘fanned-out” appear-
ance) have been identified in some studies in ALS (Noto et al.,
2011). In contrast, other studies have documented changes in
depolarizing threshold electrotonus only (Bostock et al., 1995;
Vucic and Kiernan, 2007a). Threshold electrotonus changes in
ALS increase with disease progression, associated with axonaldegeneration (Cheah et al., 2012). In addition, recovery cycle
abnormalities have also been reported in sporadic ALS – with an
increase in superexcitability identified in some studies (Vucic
and Kiernan, 2006). However, there is heterogeneity in excitability
findings, potentially reflecting differences in disease progression.
Insights into this variability have been provided by axonal
excitability studies undertaken in single motor units in ALS
patients (Howells et al., 2018a). A pattern of abnormal excitability
was identified involving increased threshold change in depolariz-
ing and hyperpolarizing threshold electrotonus, increased superx-
citability and reduced inward and outward rectification. These
changes were most pronounced in more severely affected motor
units and the extent of changes correlated to strength and fine
motor function. Mathematical modelling indicated that a reduction
in the expression of ion channels globally explained these findings,
potentially linked to failures in axoplasmic transport and delivery
of essential proteins from the motor neuron.
Excitability studies have also been undertaken across a range of
neurodegenerative disorders, some presenting as a mimic disease
of ALS. For instance, Kennedy’s disease (spinobulbomuscular atro-
phy), a slowly progressive inherited neurodegenerative disorder of
motor and sensory neurons secondary to increased expansion of
the polymorphic cytosine-adenine-guanine (CAG) repeat sequence
in the androgen receptor gene on the X chromosome, at Xq11-12,
may present as a mimic to ALS (Kennedy et al., 1968). Axonal
excitability studies in Kennedy’s disease have demonstrated pro-
longed sSD, increased depolarizing threshold electrotonus and
increased hyperpolarizing current (Vucic and Kiernan, 2007b).
Changes in sSD occurred early in Kennedy’s disease and were linked
to fasciculation frequency, suggesting that increased persistent Na+
conductance was responsible for fasciculations, and potentially
neurodegeneration. Axonal excitability studies have also identified
altered voltage dependence of HCN channels in patients with the
disease mimic benign cramp fasciculation syndrome (Czesnik
et al., 2015).
From the perspective of paediatric neurodegenerative disease,
spinal muscular atrophy (SMA) is a disorder of the spinal motor
neurons clinically characterised by development of progressive
muscle weakness and atrophy (Farrar et al., 2011). While axonal
excitability studies in less severely affected SMA patients identified
reduction in motor amplitudes without significant changes in
excitability (Farrar et al., 2011), a suite of excitability changes
occurred in more severely affected SMA patients incorporating
prolonged sSD, increased depolarizing TE and steepening of early
hyperpolarizing TE. These excitability changes were correlated
with disease severity and linked via mathematical modelling to
reduced internodal length, reduced internodal fast K+ currents
and increased nodal K+ conductances.
Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant
CAG trinucleotide expansion on chromosome 14 with variable pre-
sentation depending on the number of repeats. The disease is char-
acterized by progressive ataxia, peripheral neuropathy,
ophthalmoplegia, motor neuron loss, Parkinsonism and spasticity
(Schöls et al., 1996). Threshold tracking was carried out in patients
with Machado-Joseph disease to investigate the complaints of sev-
ere cramps in the lower extremities (Kanai et al., 2003; Farrar et al.,
2016). The main abnormality unearthed was a prolonged strength-
duration time constant suggesting increased persistent Na+-
channels. Subsequent therapy with the non-selective Na+-
blocker, mexiletine resulted in improvement of symptoms and in
the abnormalities of axonal excitability.
6.5. Metabolic neuropathy
Multiple excitability studies have been undertaken across a
spectrum of neuropathies associated with metabolic disease. Initial
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sensory axons have provided important insights into the pathogen-
esis and the development of diabetic neuropathy. In type 2 dia-
betes, a range of abnormalities has been identified including
reduction in sSD, an increase in relative refractory period, a
decrease in superexcitability and subexcitability, and a ‘‘fanning-
in” appearance of threshold electrotonus (Kuwabara et al.,
2002b; Misawa et al., 2005a,b, 2006; Krishnan et al., 2008;
Shibuta et al., 2010b; Bae et al., 2011; Sung et al., 2012; Kwai
et al., 2013). These excitability findings likely reflect altered Na+
channel function, alteration of Na+/K+ pump function, membrane
depolarization, and increase ischaemic resistance even in the sub-
clinical early stage of diabetes (Bae et al., 2011). In addition, altered
Na+ channel function would likely be responsible for neuropathic
pain and paraesthesiae, symptoms commonly experienced by
patients diagnosed with diabetic neuropathy (Misawa et al., 2009).
In terms of therapeutic intervention, abnormalities in axonal
excitability responded quickly to improvement in glycaemic con-
trol. For example, Misawa et al. (2004) demonstrated that hyper-
glycaemia shortened the refractory period, with subsequent
improvement following institution of strict glycaemic control
(Kuwabara et al., 2002b; Kitano et al., 2004; Misawa et al., 2004,
2005b; Krishnan and Kiernan, 2005). Sung et al. (2017) reported
that the development of axonal dysfunction in sensory axons
occurred prior to and in a different fashion from that experienced
by motor axons (Sung et al., 2012). Importantly, excitability studies
in sensory nerves were capable of detecting dysfunction of the axo-
nal membrane even in asymptomatic patients. In terms of longitu-
dinal approaches, changes in superexcitability, subexcitability, sSD
and threshold electrotonus become more prominent with disease
progression, and eventually the compound sensory action poten-
tial decreases, reflecting axonal loss. In contrast, the changes in
superexcitability, sSD and threshold electrotonus that develop in
motor axons, ted to occur in the later stages of disease.
In comparison, while there have been been fewer studies in
patients diagnosed with Type 1 diabetes, similar changes have
been identified in axonal excitability (Arnold et al., 2013a; Kwai
et al., 2016a,b) with an increase to ischaemic resistance (Weigl
et al., 1989; Strupp et al., 1990). In addition, studies from Kwai
and colleagues have also shown marked improvement in axonal
excitability parameters in patients treated with continuous insulin
therapy compared to other regimens (Kwai et al., 2015) and that
glycaemic variability in Type 1 diabetes is positively correlated
with axonal dysfunction (Kwai et al., 2016a). Excitability studies
have also played a key role in demonstrating the close relationship
between peripheral nerve function and morphology (assessed
using nerve ultrasound) in type 1 diabetes, a feature that is not pre-
sent in type 2 diabetes possibly due to differences in pathophysiol-
ogy (Borire et al., 2018).
Excitability studies in patients diagnosed with chronic kidney
disease have established significant changes in both motor and
sensory excitability profiles, with a decrease in sSD, a ‘‘fanned-in”
appearance of threshold electrotonus, an increase in refractoriness
and a decrease in both superexcitability and subexcitability
(Fig. 5B). These findings are consistent with axonal depolarization,
most likely driven by hyperkalaemia prior to dialysis (Kiernan
et al., 2002b; Krishnan et al., 2005b, 2006a,b,c; Arnold et al.,
2013b; Krishnan et al., 2006d). A recent randomised controlled
trial demonstrated that dietary potassium restriction is neuropro-
tective in this patient group (Arnold et al., 2017) and that a com-
posite excitability score of superexcitability with measures of
hyperpolarizing threshold electrotonus was also closer to normal
values in patients randomised to the intervention arm. In addition,
axonal excitability techniques have provided insight into the dif-
ferential effects of various haemodialysis regimens on axonal func-
tion (Arnold et al., 2013b, 2016), as well as potential neurotoxiceffects of various immune suppressants following renal transplant
(Arnold et al., 2013c), allowing for the appropriate selection of
treatment strategies involved in renal replacement. Similar
changes have been identified in critical illness polyneuropathy,
also related to extracellular potassium levels and other factors
(Z’Graggen et al., 2006).
6.6. Neurotoxicity and trauma
Chemotherapy-induced peripheral neuropathy (CIPN) is a com-
mon side-effect of many cancer treatments, producing long-term
nerve damage that significantly detracts from quality of life in can-
cer survivors. Chemotherapy typically produces sensory or sensori-
motor axonal neuropathy, although the pathophysiological
mechanisms are not well defined. Axonal excitability studies have
been utilised across a number of chemotherapy classes to provide
information regarding the mechanisms and time course of axonal
damage, with the largest body of work focusing on oxaliplatin, typ-
ically used to treat colorectal cancer (Krishnan et al., 2006; Park
et al., 2009a,b, 2011a,b; Heide et al., 2018), in addition to series
in paclitaxel (Park et al., 2011c) and patients exposed to borte-
zomib (Nasu et al., 2014). In relation to studies undertaken during
therapy with oxaliplatin, acute changes in axonal excitability
became evident shortly after infusion and could be explained on
the basis of alterations in axonal membrane Na+ channel function,
marked particularly by changes in refractoriness. Importantly,
patients who demonstrated excitability abnormalities in early
treatment were subsequently more likely to develop moderate to
severe neurotoxicity. The findings suggest that the degree of acute
nerve dysfunction may relate to the development of chronic neuro-
toxicity and that excitability could facilitate the early identification
of Na+ channel dysfunction in oxaliplatin-induced neurotoxicity.
Additionally pronounced chronic changes in refractoriness,
superexcitability and threshold electrotonus occurred in sensory
axons progressively across treatment, occurring prior to reductions
in peak amplitude, which may provide a method to identify
patients at risk for neurotoxicity (Fig. 5C).
In terms of trauma related approaches, excitability studies
undertaken immediately following spinal cord injury identified
profound changes in membrane potential, with a ‘‘fanned-in”
appearance in threshold electrotonus and reduced superexcitabil-
ity during the recovery cycle, consistent with membrane depolar-
ization (Lin et al., 2007; Boland et al., 2011). These changes in
peripheral motor axonal excitability occurred during spinal shock,
with subsequent further deterioration in axonal function, before
partial recovery ensued, in conjunction with clinical changes.
Further excitability approaches have been designed to better
chart the mechanisms of injury and recovery that may develop
with nerve trauma. For instance, following a mechanical interrup-
tion of axonal continuity, conduction may persist in the distal
stump prior to the onset of Wallerian degeneration. Experimental
excitability studies undertaken in degenerating motor axons indi-
cated a progressive increase in rheobase and increased peak
threshold deviations during both depolarizing and hyperpolarizing
electrotonus paralleled by an enhanced superexcitability of the
recovery cycle (Moldovan et al., 2009). These changes, attributed
to a nonselective loss ion channel function, could help for early
detection of ongoing axonal degeneration after mechanical injury
(Moldovan et al., 2012; Howells et al., 2018a).
Studies undertaken in patients undergoing peripheral nerve
regeneration following trauma showed marked and persistent
abnormalities in excitability: increased rheobase and sSD, larger
than normal deviations during both depolarizing and hyperpolariz-
ing threshold electrotonus and abnormalities during early recovery
cycle (Moldovan et al., 2004a, 2016; Sawai et al., 2008; Krarup and
Moldovan, 2009). It was proposed that these changes were due to
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ated nerves, combined with the increased activity-dependent Na+
influx (Tamura et al., 2006; Nakata et al., 2008). In turn, such
changes could lead to hyperactivity of the Na+/K+ pump resulting
in membrane hyperpolarization (Moldovan et al., 2004b, 2016).7. Summary
The majority of studies highlighted in these consensus guideli-
nes demonstrate that the assessment of axonal excitability may
serve as a useful technique to explore disease pathophysiology,
in addition to providing utility as a biomarker for the evaluation
of patient response to pharmacological interventions and for the
identification of neurotoxicity (Burke and Kiernan, 2018). How-
ever, few of these studies were designed as prospective, blinded
studies of diagnostic accuracy to enable the calculation of sensitiv-
ity and specificity at particular thresholds to distinguish individu-
als with disease from those without disease. As such, the use of
axonal excitability techniques to evaluate the functional response
of patients to medications or interventional strategies remains to
be validated. At present there are a number of clinical trials in neu-
rological disease states currently underway that, in addition to
providing evidence about drug efficacy, may also test the ability
of excitability to predict clinical outcome. As such, the role and
utility of axonal excitability as a surrogate measure in phase III tri-
als may serve to be more appropriately explored in a future update
of these initial consensus guidelines.Acknowledgements
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